AVH 6.48% $2.63 avita medical inc.

Ann: Quarterly Financial Report (Form 10-Q), page-43

  1. 5,869 Posts.
    lightbulb Created with Sketch. 17406
    Does this help? From the FDA SSED, June 2021 expanded use approval

    Results from the retrospective study provide sufficient initial evidence to support a 6-month shelf life for the RECELL® Device (based on available stability data provided for the activity of the Enzyme component). A prospective study assessing Enzyme stability will be performed to support future extension of the current 18-month shelf-life.

    Summary of Safety and Effectiveness - RECELL Autologous Cell Harvesting Device.pdf
 
watchlist Created with Sketch. Add AVH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.